Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study
The Oncologist · 04.07.2025 · 30 (7)
DOI: 10.1093/oncolo/oyae345 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Oncologist, online erschienen am 04.07.2025. Verfasst von Andrew J Wagner und 17 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, United States. Hauptthemen laut MEDLINE: Giant Cell Tumor of Tendon Sheath, Aminopyridines, Pyrroles. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Daiichi Sankyo, Inc.
Abstract (Originalsprache)
Background
Pexidartinib is approved in the US, Taiwan, and Korea for adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery based on the phase III ENLIVEN study (NCT02371369). We report the final long-term efficacy and safety results from ENLIVEN.
Methods
Adults with symptomatic TGCT not eligible for surgery were enrolled and randomized to pexidartinib or placebo (part 1). The blinded phase (part 1) ended at week 25; patients received pexidartinib (800 mg/day) until progression, toxicity, or study completion (part 2). This analysis includes patients who received pexidartinib at any time during ENLIVEN. Centrally reviewed overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and tumor volume score (TVS), time to response, duration of response (DOR), patient-reported outcomes (PROs), and long-term safety were assessed.
Results
Overall, 91 patients received pexidartinib. With a median follow-up of 31.2 (range: 2-66) months, ORR was 60.4% and 68.1% by RECIST and TVS, respectively. Median DOR by RECIST was not reached (range: 0.03-63.4 months). Most responses were within the first 6 months of treatment; most responders were on 800 mg vs 600/400 mg dose levels, respectively. Throughout parts 1 and 2, 3 (3%) patients had progressive disease per RECIST without dose reduction/interruption. PROs improved or were maintained. The most common grade 3/4 treatment-emergent adverse events were aspartate aminotransferase (AST) increase (9%), alanine aminotransferase (ALT) increase (10%), and hypertension (8%). Twenty-eight (31%) patients had AST or ALT ≥3 times the upper limit of normal (ULN); 17 (19%) patients had AST or ALT ≥5 times the ULN. No new safety signals were observed after long-term pexidartinib treatment.
Conclusions
Final long-term ENLIVEN results demonstrated that pexidartinib sustained clinical benefit, with increased ORR by RECIST and TVS compared to the end of the blinded phase at week 25. No new safety signals were reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, United States.
- Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, United States.
- Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital Essen, Essen 45147, Germany.
- Department of Translational Oncology, University of Duisburg-Essen, Essen 47057, Germany.
- Centre Léon Bérard and Université Claude Bernard, Lyon 69100, France.
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
ORCID-Profile: Andrew J Wagner, Sebastian Bauer, Jean-Yves Blay, John H Healey, Michiel van de Sande, Xin Ye
Förderung
- NCI NIH HHS
- Daiichi Sankyo, Inc
Zitieren
APA
Wagner, A. J., Tap, W. D., Bauer, S., Blay, J. Y., Desai, J., Gelderblom, H., Palmerini, E., Ryan, C. W., Peterfy, C., Healey, J. H., van de Sande, M., Qian, M., Shuster, D. E., Rajper, A., Ye, X., Tecson, K., Wooddell, M. J., & Stacchiotti, S. (2025). Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study. The Oncologist, 30(7). https://doi.org/10.1093/oncolo/oyae345
Vancouver
Wagner AJ, Tap WD, Bauer S, Blay JY, Desai J, Gelderblom H, et al. Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study. The Oncologist. 2025;30(7). doi:10.1093/oncolo/oyae345
BibTeX
@article{Wagner2025,
author = {Wagner, Andrew J and Tap, William D and Bauer, Sebastian and Blay, Jean-Yves and Desai, Jayesh and Gelderblom, Hans and Palmerini, Emanuela and Ryan, Christopher W and Peterfy, Charles and Healey, John H and van de Sande, Michiel and Qian, Meng and Shuster, Dale E and Rajper, Abdul and Ye, Xin and Tecson, Kristen and Wooddell, Margaret J and Stacchiotti, Silvia},
title = {Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {7},
doi = {10.1093/oncolo/oyae345}
}
EUVIMED